Alzheimer's prevention study moving forward - Phoenix Business Journal (blog)

Enlarge

Eric Reiman

Participants in the $100 million Alzheimer’s Prevention Initiative are getting their first doses of an experimental anti-amyloid antibody to see whether it will delay or prevent the disease’s onset.

I first mentioned this clinical trial in May 2012, when Dr. Eric Reiman^[1] told me how a drug called Crenezumab would be given to 3,200 people from an extraordinarily large extended family in Colombia who share a rare genetic mutation that typically triggers Alzheimer’s symptoms around age 45.

Reiman, executive director of Banner Alzheimer’s Institute, is a co-principal investigator of the Phoenix-based trial. Dr. Pierre Tariot^[2] , director of BAI, is the other principal investigator.

“There is no guarantee that the investigational treatment will work, but there is only one way to find out,” Reiman said.

Click here for the full story^[3] .

Angela Gonzales covers health, biotech and education.

References

1. ^{^} Eric Reiman (www.bizjournals.com)


2. ^{^} Pierre Tariot (www.bizjournals.com)


3. ^{^} Click here for the full story (%20bit.ly)